DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Piperaquine
Piperaquine
Eurartesim, INN-Piperaquine & INN-Artenimol
Pharmacological and Cardiovascular Perspectives on the Treatment of COVID-19 with Chloroquine Derivatives
Plasmodium Falciparum Clinical Isolates: in Vitro Genotypic and Phenotypic Characterization Nonlawat Boonyalai1* , Brian A
Downloaded and Saved in PDB Format
Treatment Failure Due to the Potential Under-Dosing of Dihydroartemisinin-Piperaquine in a Patient with Plasmodium Falciparum Uncomplicated Malaria
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
Medical Review(S) Review of Request for Priority Review
Current Antimalarial Therapies and Advances in the Development of Semi-Synthetic Artemisinin Derivatives
Malaria Chemoprevention with Monthly Dihydroartemisinin
Piperaquine Antimalarial Product Across Intestinal Membranes Sunday O
Surveillance for Falsified and Substandard Medicines in Africa and Asia by Local Organizations Using the Low-Cost GPHF Minilab
Piperaquine for the Post-Discharge Management of Severe
Drug Repositioning in the Treatment of Malaria and TB
Drug Repurposing: a Review of Old and New Antibiotics for the Treatment of Malaria: Identifying Antibiotics with a Fast Onset of Antiplasmodial Action
Dondorp, Background on Malaria and Combination Anti-Malarial Drug Therapy
Resistance to Artemisinin Combination Therapies (Acts): Do Not Forget the Partner Drug!
Cdc 20682 DS1.Pdf
Bioprospecting of Nitrogenous Heterocyclic Scaffolds With
Top View
Drugs for Parasitic Infections (2013 Edition)
Development of Copy Number Assays for Detection and Surveillance Of
Piperaquine and Chloroquine Against Plasmodium Vivax Malaria, Cambodia
Status Report on Artemisinin Resistance
Identification of Trypanosoma Cruzi Growth Inhibitors with Activity In
210795Orig1s000
Who-Pq Recommended Summary of Product Characteristics
In Vitro Evaluation of the Antiviral Activity of Methylene Blue Alone Or in Combination Against SARS-Cov-2
The Cardiotoxicity of Antimalarials
And Aspirin- Mediated Protective Role of HSP70 and HSP90 As Modes to Strengthen the Natural Immunity Against Potent SARS-Cov-2
COVID-19: Chloroquine and Hydroxychloroquine Research
Download Author Version (PDF)
WO 2007/028413 Al
Lumefantrine and Piperaquine: Mechanisms of Resistance
Eurartesim; INN: Piperaquine Tetraphosphate/Dihydroartemisinin
Intravenous Artesunate Plus Oral Dihydroartemisinin–Piperaquine Or
Mechanisms Associated with Trypanosoma Cruzi Host Target Cell Adhesion, Recognition and Internalization
Choreoathetosis – an Unusual Adverse Effect of Dihydroartemisinin
COVID-19: an Update About the Discovery Clinical Trial
Antimalaria Drug Development & Pipeline
Malaria Prevention in Travellers from the UK 2021
Guidelines for the Treatment of Malaria
Assessment of Spectroscopic Interaction of Lamivudine/Metronidazole with Dihydroartemisinin – Piperaquine Antimalarial Tablet
Piperaquine Resistance in Plasmodium Falciparum Malaria in Cambodia: a Multisite Prospective Cohort Study
A Mechanism of Resistance and Mode of Action for Drugs Against Plasmodium Falciparum
Population Pharmacokinetics of Mefloquine, Piperaquine And
Evolvement of EU Regulations on Innovative Medicines’ Was Accepted for Poster Presentation at the 77Th International Pharmaceutical Federation
[Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
Confidential Clinical Trial Protocol
The Selection and Use of Essential Medicines
Piperaquine Concentration and Malaria Treatment Outcomes In
Plasmodium Falciparum to Guide Anti‑Malarial Drug Policy Decisions in Sub‑Saharan Africa: Opportunities and Challenges Deus S
Assessment of Hydroxychloroquine and Chloroquine Safety Profiles – a Systematic Review and Meta-Analysis
Plasmodium Falciparum Megan R
Efficacy of Quinine, Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine As Rescue Treatment for Uncomplicated Malaria in Ugandan Children
Severe Malaria Not Responsive to Artemisinin Derivatives in Man Returning from Angola to Vietnam
CHAPTER E26 Pharmacology of Agents Used to Treat Parasitic Infections
Curriculum Vitae Steven Richard Meshnick, MD, Ph.D Birthdate: 4 April 1952